" The granted US patent is of high importance in the context of potential future commercialization of CAN04 in this strategically important market", says Damian Marron, Interim CEO of Cantargia. "We continue to progress our program in PDAC with the development of a validated diagnostic method to enable the selection of patients with high IL1RAP levels for future studies."